Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
. 1984 Mar;51(3):316–320. doi: 10.1136/hrt.51.3.316

The QT interval: a predictor of the plasma and myocardial concentrations of amiodarone.

N M Debbas, C du Cailar, R S Bexton, J G Demaille, A J Camm, P Puech
PMCID: PMC481505  PMID: 6696809

Abstract

A study was performed to assess whether plasma and myocardial concentrations of amiodarone correlated with changes on the surface electrocardiogram. Nine patients--seven with angina and two with paroxysmal ventricular tachycardia--were treated with oral amiodarone (200-400 mg daily) for at least nine months before undergoing cardiac surgery. QT intervals were measured from lead II of the surface electrocardiograms recorded before amiodarone treatment and immediately before surgery. Patients with prominent U waves after taking amiodarone were excluded from the study. Plasma and myocardial samples were collected at the beginning of the surgical procedure for estimating plasma and myocardial concentrations using the high performance liquid chromatographic technique. Amiodarone caused a significant lengthening of the QTc interval. There was a good correlation between plasma and myocardial concentrations, and both correlated well with the percentage increase in the QTc interval. Although there was a strong correlation between the dosage given (mg/kg/day) and both plasma and myocardial concentrations, the correlation with the percentage increase in the QTc interval was weaker but still highly significant. Despite previous reports to the contrary, the findings indicate that the plasma concentration of amiodarone does correlate well with the myocardial concentration. The degree of lengthening of the QTc interval may be used clinically to estimate the myocardial concentration of amiodarone.

Full text

PDF
316

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bexton R. S., Camm A. J. Drugs with a class III antiarrhythmic action. Pharmacol Ther. 1982;17(3):315–355. doi: 10.1016/0163-7258(82)90020-1. [DOI] [PubMed] [Google Scholar]
  2. Broekhuysen J., Laruel R., Sion R. Recherches dans la série des benzofurannes. XXXVII. Etude comparée du transit et du métabolisme de l'amiodarone chez diverses espèces animales et chez l'homme. Arch Int Pharmacodyn Ther. 1969 Feb;177(2):340–359. [PubMed] [Google Scholar]
  3. CHARLIER R., DELTOUR G., TONDEUR R., BINON F. [Studies in the benzofuran series. VII. Preliminary pharmacological study of 2-butyl-3-(3,5-diiodo-4-beta-N-diethylaminoethoxybenzoyl)-benzofuran]. Arch Int Pharmacodyn Ther. 1962 Sep 1;139:255–264. [PubMed] [Google Scholar]
  4. Debbas N. M., Du Cailar C., Sassine A., Derancourt J., Demaille J. G., Puech P. Determination of cardiac and plasma drug levels during long-term amiodarone therapy. Eur J Clin Invest. 1983 Apr;13(2):123–127. doi: 10.1111/j.1365-2362.1983.tb00076.x. [DOI] [PubMed] [Google Scholar]
  5. Delage C., Lagacé R., Huard J. Pseudocyanotic pigmentation of the skin induced by amiodarone: a light and electron microscopic study. Can Med Assoc J. 1975 May 17;112(10):1205–1208. [PMC free article] [PubMed] [Google Scholar]
  6. Flanagan R. J., Storey G. C., Holt D. W. Rapid high-performance liquid chromatographic method for the measurement of amiodarone in blood plasma or serum at the concentrations attained during therapy. J Chromatogr. 1980 Jan 18;187(2):391–398. doi: 10.1016/s0021-9673(00)80471-9. [DOI] [PubMed] [Google Scholar]
  7. Heger J. J., Prystowsky E. N., Jackman W. M., Naccarelli G. V., Warfel K. A., Rinkenberger R. L., Zipes D. P. Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation. N Engl J Med. 1981 Sep 3;305(10):539–545. doi: 10.1056/NEJM198109033051002. [DOI] [PubMed] [Google Scholar]
  8. Holt D. W., Tucker G. T., Jackson P. R., Storey G. C. Amiodarone pharmacokinetics. Am Heart J. 1983 Oct;106(4 Pt 2):840–847. doi: 10.1016/0002-8703(83)90006-6. [DOI] [PubMed] [Google Scholar]
  9. Marcus F. I., Fontaine G. H., Frank R., Grosgogeat Y. Clinical pharmacology and therapeutic applications of the antiarrhythmic agent amiodarone. Am Heart J. 1981 Apr;101(4):480–493. doi: 10.1016/0002-8703(81)90140-x. [DOI] [PubMed] [Google Scholar]
  10. Pritchard D. A., Singh B. N., Hurley P. J. Effects of amiodarone on thyroid function in patients with ischaemic heart disease. Br Heart J. 1975 Aug;37(8):856–860. doi: 10.1136/hrt.37.8.856. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Rosenbaum M. B., Chiale P. A., Halpern M. S., Nau G. J., Przybylski J., Levi R. J., Lázzari J. O., Elizari M. V. Clinical efficacy of amiodarone as an antiarrhythmic agent. Am J Cardiol. 1976 Dec;38(7):934–944. doi: 10.1016/0002-9149(76)90807-9. [DOI] [PubMed] [Google Scholar]
  12. Singh B. N., Vaughan Williams E. M. A third class of anti-arrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474. Br J Pharmacol. 1970 Aug;39(4):675–687. doi: 10.1111/j.1476-5381.1970.tb09893.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Singh B. N., Vaughan Williams E. M. The effect of amiodarone, a new anti-anginal drug, on cardiac muscle. Br J Pharmacol. 1970 Aug;39(4):657–667. doi: 10.1111/j.1476-5381.1970.tb09891.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Vos A. K., van Ramshorst A. G., Grosfeld J. C., Goossens J. P. A peculiar cutaneous pigmentation from cordarone. Dermatologica. 1972;145(5):297–303. doi: 10.1159/000252057. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES